Glaukos Announces FDA Approval of iDose TR (travoprost intracameral implant)
14.12.2023 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the U.S. Food and Drug Administration ... Seite 1
Source: wallstreet-online.de